Endocrine Research Updates

For Medical Professionals

Pharmacist and customer looking at medication box
Younger adults with diabetes (age 18 to 39 years) are less likely than older patients to take medication to control their glucose levels or to see a doctor biannually.
An investigational oral formulation of octreotide was found to be safe and effective in the treatment of acromegaly in a phase 3 open-label study published online ahead of print in the Journal of Clinical Endocrinology & Metabolism.
Young woman looking in the refrigerator at late evening
The U.S. Food and Drug Administration (FDA) expanded the approved uses of Vyvanse® (lisdexamfetamine dimesylate) to include treatment of moderate-to-severe binge-eating disorder in adults, making it the first medication approved to treat this condition.
Brain outline in red pencil
People who develop diabetes in middle-age are more likely to experience significant memory and cognitive problems over the next 20 years compared to people without diabetes in midlife, according to a prospective cohort study.
Pancreatic islet cell normal and type 1 diabetic
Researchers discussed the latest advances in cell replacement therapy for the treatment of type 1 diabetes in the January issue of Endocrinology.
Glucometer pictured as part of glucose management
The findings of this important paper emphasize one specific word: early. It is important to treat these patients with type 1 aggressively and early, when they are either adolescent or young adults, or as soon as they are diagnosed if they are diagnosed in their 20s.
Cropped image of male doctor with prescription medicine bottle in clinic
Glyxambi is now approved as an adjunct to nutrition and physical activity for the treatment of adults with type 2 diabetes mellitus. Glyxambi, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, is the first diabetes treatment in the United States to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
woman with smart phone, resting after gym workout
Studies suggest that up to 20% of people with type 2 diabetes may be exercise resistant—meaning that they do not see any improvement in glucose level when following a supervised exercise regimen, according to a systematic review.
Researchers have developed a multistep protocol that converts human embryonic stem cells into insulin-producing cells that can reverse diabetes in approximately 40 days in an animal model—much faster than the 4 months required for cells produced with previous methods. The goal is to be able transplant these insulin-producing cells for the treatment of type 1 diabetes, researchers reported in a study published in the November issue of Nature Biotechnology.
highlight on legs and feet
Spinal cord stimulation (SCS) reduced pain more effectively than optimal medical treatment in a study of patients with moderate to severe diabetic peripheral neuropathy in their lower limbs, as reported in the November issue of Diabetes Care. Spinal cord stimulation is not without risks, as one treatment-related fatality was reported in this study.
older man using a glucometer
According to a prospective cohort study published online ahead of print in The Spine Journal, patients with type 2 diabetes had significant reductions in A1C levels following decompression spine surgery to treat lumbar spinal stenosis.
Doctor holding a biopsy syringe
Repeat fine-needle aspiration following a nondiagnostic result detected malignancy in less than 1% of cases, according to findings reported in the September issue of Radiology. The authors suggest that ultrasound followup may be more appropriate than repeat fine-needle aspiration in patients with initially nondiagnostic results from thyroid nodule biopsy.
Illustration of thyroid gland and nodule
A link between autoimmune thyroiditis and differentiated thyroid cancer was found in a surgical series of patients undergoing thyroidectomy but not in a cytological series of patients who underwent fine-needle aspiration, according to findings from a retrospective study published in the September issue of the Journal of Clinical Endocrinology and Metabolism.
pregnant woman reading on her laptop
Hyperthyroidism and high-normal free T4 levels in pregnancy are associated with an increased risk for pregnancy-induced hypertension and preeclampsia, according to findings from a population-based cohort study. The study was published online ahead of print in the Journal of Clinical Endocrinology and Metabolism.
Diabetes education
The U.S. Preventive Services Task Force (USPSTF) has issued a draft recommendation regarding screening for abnormal blood glucose levels in all adults at increased risk for type 2 diabetes.
Colorful cogs in the brain depicting mental function
Weight loss from bariatric surgery appears to reverse the increased cerebral metabolism and poor executive function associated with obesity, according to a study reported in the August 26 Journal of Clinical Endocrinology and Metabolism.
womans feet on a acale with an apple and a tape measure
Members of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14-1 in favor of approving the once-daily human GLP-1 analogue liraglutide for the treatment of obesity.
overweight woman holding fruit and vegetables
The U.S. Food and Drug Administration (FDA) has approved the combination agent naltrexone/bupropion (Contrave) extended release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese (BMI ≥ 30 kg/m2) or overweight (27 kg/m2) and have at least one weight-related comorbidity, including hyperension, type 2 diabetes, and dyslipidemia.
Insulin dripping from the end of an injection pen
Dulaglutide (Trulicity), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is now approved as an adjunct to diet and exercise in the treatment of type 2 diabetes in adults.
Type 1 Diabetes being handwritten in red on screen
The U.S. Food and Drug Administration (FDA) approved for marketing the first zinc transporter 8 autoantibody (ZnT8Ab) test to aid in the diagnosis of type 1 diabetes.